Effects of intravenous infusion of lipid-free apo A-I in humans

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 9, 1996, Pages 1203-1214

  Nanjee, M N ^a   Crouse, J R ^b   King, J M ^b   Hovorka, R ^c   Rees, S E ^c   Carson, E R ^c   Morgenthaler, J J ^d   Lerch, P ^d   Miller, N E ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c CITY UNIVERSITY   (United Kingdom)

^d Central Laboratory in Bern   (Switzerland)

Author keywords

apo A 1; cholesterol; HDL; phospholipids; triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTRALIPID; PHOSPHOLIPID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029737826     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.9.1203     Document Type: Article

References (82)

1. Brewer HB Jr, Fairwell T, Larue A, Ronan R, Houser A, Bronzert TJ. The amino-acid sequence of human apolipoprotein A-I isolated from HDL. Biochem Biophys Res Commun. 1978;80:623-630.
2. Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of the human apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1983;84:6147-6151.
3. Zannis VI, Karathanasis SK, Keutmann HT, Goldberger G, Breslow JL. Intracellular and extracellular processing of apolipoprotein A-I: secreted apolipoprotein A-I isoprotein 2 is a propeptide. Proc Natl Acad Sci U S A. 1983;80:2574-2578.
4. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high density lipoprotein. Biochemistry. 1988;27:25-29.
5. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984;25:1017-1058.
6. Pittman RC, Steinberg D. Sites and mechanisms of uptake and degradation of high density and low density lipoproteins. J Lipid Res. 1984;25:1577-1585.
7. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 1993;91:1743-1752.
8. Barbaras R, Collet X, Chap H, Perret B. Specific binding of free apolipoprotein A-I to a high-affinity binding site on HepG2 cells: characterization of two high-density lipoprotein sites. Biochemistry. 1994;33:2335-2340.
9. Senault C, Vacher D, Sakr S, Girard-Globa A. Binding of HDL to basolateral membranes of the renal cortex: evidence for two components in the HDL membrane association. Biochim Biophys Acta. 1994;1189:168-174.
10. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987;113:589-597.
11. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
12. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Notfze DK, Dolphin PJ, Edelglass DD, Bogorad DD, Alaupovic P. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary artery disease. N Engl J Med. 1982;306:1513-1519.
13. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr. Plasma apolipoprotein A-I absence associated with a marked reduction of high-density lipoproteins and premature coronary artery disease. Arteriosclerosis. 1982;2:16-26.
14. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogencsis in transgenic mice by human apolipo-protein AI. Nature. 1991;353:265-267.
15. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
16. Liu AC, Lawn RM, Verstuyft JG, Rubin EM. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein(a) in transgenic mice. J Lipid Res. 1994;35:2263-2267.
17. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterolfed rabbit. J Clin Invest. 1990;85:1234-1241.
18. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y-I, Naito M, Ruan Y, Takahashi K, Ohta T, Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Anerioscler Thromb Vase Biol. 1995;15:1882-1888.
19. Beitz J, Beitz A, Antonov IV, Misharin AY, Mest HJ. Does a HDL injection reduce the development of serum hyperlipidemia and progression of fatty streaks in cholesterol fed rabbits? Prostaglandins Leukot Essent Fatty Acids. 1992;47:149-152.
20. Mezdour H, Yamamura T, Nomura S, Yamamoto A. Exogenous supply of artificial lipoproteins does not decrease susceptibility to atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 1995;113:237-246.
21. Li H, Reddick RL, Maeda N. Lack of apo A-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb. 1993;13:1814-1821.
22. Assmann G, Von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol and coronary artery disease: insights from mutations. Circulation. 1993;87(suppl III):III-28-III-34.
23. Stein O, Vanderhoek J, Stein Y. Cholesterol content and sterol synthesis in human skin fibroblasts and rat aortic smooth muscle cells exposed to lipoprotein-depleted serum and high density apolipoprotein/phospholipid mixtures. Biochim Biophys Acta. 1976;431:347-358.
24. Picardo M, Massey JB, Kuhn DE, Gotto AM Jr, Gianturco SH, Pownall HJ. Partially reassembled high density lipoproteins: effects on cholesterol flux, synthesis, and esterification in normal human skin fibroblasts. Arteriosclerosis. 1986;6:434-441.
25. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
26. Kawano M, Miida T, Fielding CJ, Fielding PE. Quantitation of preβ-HDL dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochemistry. 1993;32:5025-5028.
27. Miida T, Kawano M, Fielding CJ, Fielding PE. Regulation of the concentration of preβ high-density lipoprotein in normal plasma by cell membranes and lecithin-cholesterol acyltransferase activity. Biochemistry. 1992;31:11112-11117.
28. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages: formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem. 1991;266:3080-3086.
29. Hara H, Yokoyama S. Role of apolipoproteins in cholesterol efflux from macrophages to lipid microemulsion: proposal of a putative model for the pre-β high-density lipoprotein pathway. Biochemistry. 1992;31:2040-2046.
30. Forte TM, Goth-Goldstein R, Nordhausen RW, McCall MR. Apolipoprotein AI-cell membrane interaction: extracellular assembly of heterogeneous nascent HDL particles. J Lipid Res. 1993;34:317-324.
31. Forte TM, Bielicki JK, Goth-Goldstein R, Selmek J, McCall MR. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J Lipid Res. 1995;36:148-157.
32. Bielicki JK, Johnson WJ, Weinberg RB, Glick JM, Rothblat GH. Efflux of lipid from fibroblasts to apolipoproteins: dependence on elevated levels of cellular unesterified cholesterol. J Lipid Res. 1992;33:1699-1709.
33. Lefevre M, Sloop CH, Roheim PS. Characterization of dog prenodal peripheral lymph lipoproteins: evidence for the peripheral formation of lipoprotein-unassociated apo A-I with slow pre-beta electrophoretic mobility. J Lipid Res. 1988;29:1139-1148.
34. Asztalos BF, Roheim PS. Presence and formation of "free apolipoprotein A-like" particles in human plasma. Argterioscler Thromb Vase Biol. 1995;15:1419-1423.
35. Clay MA, Newnham HH, Forte TM, Barter PJ. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim Biophys Acta. 1992;1124:52-58.
36. Liang H-Q, Rye K-A, Barter PJ. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J Lipid Res. 1994;35:1187-1199.
37. Miller NE. Is cholesterol efflux from cells coupled to the lipolysis of triglyceride-rich lipoproteins? In: Miller NE, Tall AR, eds. High Density Lipoproteins and Atherosclerosis III. Amsterdam, Netherlands: Excerpta Medica; 1992:191-197.
38. Nichols AV, Gong EL, Blanche PJ, Forte TM. HDL populations: origins and interconversions. In: Miller NE, ed. High Density Lipoproteines and Atherosclerosis II. Amsterdam, Netherlands: Excerpta Medica; 1989:159-171.
39. Lerch PG, Morgenthaler J-J, Peitsch MC, Freidli H, Hodler G, Doran JE, Isliker H, Heiniger H-J. Isolation and properties of apolipoprotein A for therapeutic use. In: Poulik MD, Hobbs JR, Mestecky J, Miller NE, eds. Protides of the Biological Fluids. Oxford, England: Pergamon; 1989:409-416.
40. Peitsch MC, Kress A, Lerch PG, Morgenthaler J-J, Isliker H, Heiniger H-J. A purification method for apolipoprotein A-I and A-II. Anal Biochem. 1989;178:301-305.
41. Osborne JC Jr, Schaefer EJ, Powell GM, Lee NS, Zech LA. Molecular properties of radioiodinated apolipoprotein A-I. J Biol Chem. 1984;259:347-353.
42. Forte TM, Nordhansen RW. Electron microscopy of negatively stained lipoproteins. Methods Enzymol. 1986;128:442-457.
43. Lerch PG, Moudry R, Doran JE, Hubsch A, Omar A, Morgenthaler J-J, Isliker H, Heiniger H-J. In vitro characteristics of reconstituted HDL for therapy. Proceedings of European Lipoprotein Club. Bruge, Belgium: European Lipoprotein Club; 1992. Abstract.
44. Demacker PNM, Hijmans AGM, Vos-Janssen HE, Van't Laar A, Jansen AP. A study of the use of polyethylene glycol in estimating cholesterol in high density lipoprotein. Clin Chem. 1980;26:1775-1779.
45. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoproteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
46. Berman M, Weiss MF. SAAM Manual. Washington, DC: National Institutes of Health; 1978. US Department of Health, Education, and Welfare publication NIH 78-180.
47. Carson ER, Cobelli C, Finkelstein L. The Mathematical Modeling of Metabolic and Endocrine Systems. New York, NY: John Wiley and Sons; 1983.
48. Aviram M. Williams KJ, Mclntosh RA, Carpentier YA, Tall AR, Deckelbaum RJ. Intralipid infusion abolishes ability of human serum to cholesterol-load cultured macrophages. Arteriosclerosis. 1989;9:67-75.
49. Shepherd J, Packard CJ, Gotto AM Jr, Taunton OD. Comparison of two methods to investigate the metabolism of human apolipoproteins A-I and A-II. J Lipid Res. 1978;19:656-661.
50. Magill P, Rao SN, Miller NE, Nicoll A, Brunzell J, St Hilaire J, Lewis B. Relationships between the metabolism of high-density and verylow-density lipoproteins in men: studies of apolipoprotein kinetics and lipoprotein lipase activity. Eur J Clin Invest. 1982;12:113-120.
51. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo AII fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 1991;87:536-544.
52. Schaefer EJ, Zech LA, Jenkins LL, Bronzert TJ, Rubalcaba EA, Lindgren FT, Aamodt RL, Brewer HB Jr. Human apolipoprotein A-I and A-II metabolism. J Lipid Res. 1982;23:850-862.
53. Gylling H, Vega GL, Grundy SM. Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res. 1992;33:1527-1539.
54. Shepherd J, Gotto AM Jr, Taunton OD, Caslake MJ, Parish E. The in vitro interaction of human apolipoprotein A-I and high density lipoproteins. Biochim Biophys Acta. 1977;489:486-501.
55. Ha YC, Trifunovic Z, Howlett GJ. Human apolipoprotein A-I forms small high density lipoprotein particles in rats in vivo. Biochim Biophys Acta. 1992;1125:223-229.
56. Malmendier CL, Delcroix C, Ameryckx JP. In vivo metabolism of human apoprotein A-I-phospholipid complexes: comparison with human high density lipoprotein-apoprotein A-I metabolism. Clin Chim Acta. 1983;131:201-210.
57. Vega GL, Gylling H, Nichols AV, Grundy SM. Evaluation of a method for study of kinetics and autologous apolipoprotein A-I. J Lipid Res. 1991;32:867-875.
58. Schreyer SA, Hart LK, Attie AD. Hypercatabolism of lipoprotein-free apolipoprotein A-I in HDL-deficient mutant chickens, Arterioscler Thromb. 1994;14:2053-2059.
59. Schmidt HH-J, Remaley AT, Stonik JA, Ronan R, Wellmann A, Thomas F, Zech LA, Brewer HB Jr, Hoeg JM. Carboxyl-terminal domain truncation alters apolipoprotein A-I m vivo catabolism. J Biol Chem. 1995;270:5469-5475.
60. Fisher WR, Venkatakrishnan V, Zech LA, Hall CM, Kilgore LL, Stacpoole PW, Diffenderfer MR, Friday KE, Sumner AE, Marsh JB. Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A-I in humans. J Lipid Res. 1995;36:1618-1628.
61. Yokoyama S, Tajima S, Yamamoto A. The process of dissolving apolipoprotein A-I in an aqueous buffer. J Biochem. 1982;91:1267-1272.
62. 2: relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest. 1987;80:341-347.
63. Simard G, Perret B, Durand S, Collet X, Chap H, Douste-Blazy L, Phosphatidylcholine and triacylglycerol hydrolysis in HDL as induced by hepatic lipase: modulation of the phospholipase activity by changes in the particle surface or in the lipid core. Biochim Biophys Acta. 1989;1001:225-233.
64. Kubo M, Matsuzawa Y, Tajima S, Ishikawa K, Yamamoto A, Tarui S. Apo A-I and apo A-II inhibit hepatic triglyceride lipase form human postheparin plasma. Biochem Biophys Res Commun. 1981;100:261-266.
65. 2triacylglycerols. Biochim Biophys Acta. 1982;713:292-299.
66. Jahn CE, Osborne JC Jr, Schaefer EJ, Brewer HB Jr. Activation of the enzymic activity of hepatic lipase by apolipoprotein A-II: characterization of a major component of high density lipoprotein as the activating plasma component in vitro. Eur J Biochem. 1983;131:25-29.
67. Guyard-Dangremont V, Lagrost L, Gambert P. Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. J Lipid Res. 1994;35:982-992.
68. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies, Biochim Biophys Acta. 1994;1215:209-236.
69. Nicoll A, Lewis B. Evaluation of the roles of lipoprotein lipase and hepatic lipase in lipoprotein metabolism: in vivo and in vitro studies in man. Eur J Clin Invest. 1980;10:487-495.
70. Goldberg IJ, Le N-A, Paterniti JR Jr, Ginsberg HN, Lindgren FT, Brown WV. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J Clin Invest, 1982;70:1184-1192.
71. Demant T, Carlson LA, Holmquist L, Karpe F, Nilsson-Ehle P, Packard CJ, Shepherd J. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res. 1988,29:1603-1611.
72. Hegele RA, Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJA, Connelly PW. Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb. 1993;13:720-728.
73. Breckenridge WC, Little JA, Alaupovic P, Wang CS, Kuksis A, Kakis G, Lindgren F, Gardiner G. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 1982;45:161-179.
74. Connelly PW, Maguire GF, Lee M, Little JA. Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis. 1990;10:40-48.
75. Dahiya R, Sharma A, Ahlawat RS. Inhibition of lipoprotein lipase activity by high density lipoprotein and apolipoproteins C, E and A in rhesus monkeys. Indian J Med Res. 1990;92:115-119.
76. Jones SMA, Younan SIM, Graham A, Rogers MP. Inhibition of human and rat lipoprotein lipase by high-density lipoprotein. Biochim Biophys Acta. 1986;878:250-257.
77. Olefsky J, Farquhar JW, Reaven GM. Sex difference in the kinetics of triglyceride metabolism in normal and hypertriglyceridaemic human subjects. Eur J Clin Invest. 1974;4:121-127.
78. Kekki M, Nikkila EA. Turnover of plasma total and very low density lipoprotein triglyceride in man. Scond J Clin Lab Invest 1975;35:171-179.
79. Hardardottir l, Grunfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol. 1994;5:207-215.
80. Fried SK, Zechner R. Cachectin/tumor or necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J Lipid Res. 1989;30:1917-1923.
81. Fong Y, Marano MA, Moldawer LL, Wei H, Galvano SE, Kenney JS, Allison AC, Cerami A, Shires GT, Lowry SF. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest. 1990;85:1896-1904.
82. Burrell R. Human responses to bacterial endotoxin. Circulatory Shock. 1994;43:137-153.